LENZ Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations And Comprehensive Loss
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Product sales, net | $1,588 | $— |
| License revenue | 17,500 | — |
| Total revenue | 19,088 | — |
| Operating expenses: | ||
| Cost of sales | 418 | — |
| Selling, general and administrative | 91,138 | 28,809 |
| Research and development | 18,670 | 29,801 |
| Total operating expenses | 110,226 | 58,610 |
| Loss from operations | (91,138) | (58,610) |
| Other income: | ||
| Other (expense) income | (243) | 289 |
| Interest income | 9,756 | 8,553 |
| Total other income, net | 9,513 | 8,842 |
| Net loss before income taxes | (81,625) | (49,768) |
| Income tax expense | 502 | 1 |
| Net loss | $(82,127) | $(49,769) |
| Other comprehensive income (loss): | ||
| Unrealized gain on marketable securities | 46 | 190 |
| Comprehensive loss | $(82,081) | $(49,579) |
| Net loss per share, basic and diluted | $(2.85) | $(2.34) |
| Weighted-average common shares outstanding, basic and diluted | 28,813,164 | 21,281,038 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.